Harvard Bioscience Statistics
Total Valuation
HBIO has a market cap or net worth of $17.18 million. The enterprise value is $57.57 million.
Important Dates
The next estimated earnings date is Tuesday, May 6, 2025, before market open.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HBIO has 44.07 million shares outstanding. The number of shares has increased by 2.64% in one year.
| Current Share Class | 44.07M |
| Shares Outstanding | 44.07M |
| Shares Change (YoY) | +2.64% |
| Shares Change (QoQ) | +1.93% |
| Owned by Insiders (%) | 7.57% |
| Owned by Institutions (%) | 53.51% |
| Float | 31.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 8.66 |
| PS Ratio | 0.18 |
| Forward PS | 0.18 |
| PB Ratio | 0.27 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 11.93 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.61 |
| EV / EBITDA | 23.59 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.82, with a Debt / Equity ratio of 0.70.
| Current Ratio | 0.82 |
| Quick Ratio | 0.35 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | 9.65 |
| Debt / FCF | n/a |
| Interest Coverage | -1.47 |
Financial Efficiency
Return on equity (ROE) is -18.19% and return on invested capital (ROIC) is -2.63%.
| Return on Equity (ROE) | -18.19% |
| Return on Assets (ROA) | -2.23% |
| Return on Invested Capital (ROIC) | -2.63% |
| Return on Capital Employed (ROCE) | -6.58% |
| Revenue Per Employee | $265,169 |
| Profits Per Employee | -$34,944 |
| Employee Count | 355 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 1.64 |
Taxes
In the past 12 months, HBIO has paid $740,000 in taxes.
| Income Tax | 740,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.58% in the last 52 weeks. The beta is 1.47, so HBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.47 |
| 52-Week Price Change | -89.58% |
| 50-Day Moving Average | 0.69 |
| 200-Day Moving Average | 2.03 |
| Relative Strength Index (RSI) | 31.26 |
| Average Volume (20 Days) | 360,363 |
Short Selling Information
The latest short interest is 1.05 million, so 2.38% of the outstanding shares have been sold short.
| Short Interest | 1.05M |
| Short Previous Month | 1.05M |
| Short % of Shares Out | 2.38% |
| Short % of Float | 3.31% |
| Short Ratio (days to cover) | 2.88 |
Income Statement
In the last 12 months, HBIO had revenue of $94.14 million and -$12.41 million in losses. Loss per share was -$0.28.
| Revenue | 94.14M |
| Gross Profit | 54.81M |
| Operating Income | -4.72M |
| Pretax Income | -9.43M |
| Net Income | -12.41M |
| EBITDA | 2.44M |
| EBIT | -4.72M |
| Loss Per Share | -$0.28 |
Full Income StatementBalance Sheet
The company has $4.11 million in cash and $44.50 million in debt, giving a net cash position of -$40.39 million or -$0.92 per share.
| Cash & Cash Equivalents | 4.11M |
| Total Debt | 44.50M |
| Net Cash | -40.39M |
| Net Cash Per Share | -$0.92 |
| Equity (Book Value) | 63.34M |
| Book Value Per Share | 1.44 |
| Working Capital | -9.84M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $1.44 million and capital expenditures -$2.64 million, giving a free cash flow of -$1.20 million.
| Operating Cash Flow | 1.44M |
| Capital Expenditures | -2.64M |
| Free Cash Flow | -1.20M |
| FCF Per Share | -$0.03 |
Full Cash Flow StatementMargins
Gross margin is 58.22%, with operating and profit margins of -5.01% and -13.18%.
| Gross Margin | 58.22% |
| Operating Margin | -5.01% |
| Pretax Margin | -12.39% |
| Profit Margin | -13.18% |
| EBITDA Margin | 2.59% |
| EBIT Margin | -5.01% |
| FCF Margin | n/a |
Dividends & Yields
HBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.64% |
| Shareholder Yield | -2.64% |
| Earnings Yield | -72.19% |
| FCF Yield | -7.01% |
Analyst Forecast
The average price target for HBIO is $4.50, which is 1,054.14% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.50 |
| Price Target Difference | 1,054.14% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HBIO has an Altman Z-Score of 0.13 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.13 |
| Piotroski F-Score | 2 |